Search results
Results From The WOW.Com Content Network
The McDonald criteria are diagnostic criteria for multiple sclerosis (MS). These criteria are named after neurologist W. Ian McDonald who directed an international panel in association with the National Multiple Sclerosis Society (NMSS) of America and recommended revised diagnostic criteria for MS in April 2001.
The Poser diagnosis criteria for MS does not allow doctors normally to give an MS diagnosis until a second attack takes place. Therefore, the concept of "clinical MS", for a MS that can be diagnosed is sometimes too strong because until MS diagnosis has been established, nobody can tell whether the disease dealing with is MS. [citation needed]
Multiple sclerosis diagnosis can only be made when there is proof of lesions disseminated in time and in space. Therefore, when damage in the CNS is big enough to be seen. It would be desirable to make it faster. The ideal diagnosis schema would be able to determine for any given subject, if he will develop MS, at any point in his life, and when.
Display a year or month calendar Template parameters [Edit template data] Parameter Description Type Status Year year the ordinal year number of the calendar Default current Number suggested Month month whether to display a single month instead of a whole year, and which one Default empty Example current, next, last, 1, January String suggested Show year show_year whether to display the year ...
A new study found that in about 10% cases of multiple sclerosis, the body begins producing a distinctive set of antibodies against its own proteins years before symptoms emerge. “Multiple ...
Christina Applegate says dealing with multiple sclerosis has been a real struggle that not everyone can fully understand in a new interview with Vanity Fair.
Tumefactive multiple sclerosis is a condition in which the central nervous system of a person has multiple demyelinating lesions with atypical characteristics for those of standard multiple sclerosis (MS). It is called tumefactive as the lesions are "tumor-like" and they mimic tumors clinically, radiologically and sometimes pathologically.
In fact, it seems that MS patients with anti-MOG positivity could be considered a different disease in the near future. Comparative Effectiveness Research (CER) is an emerging field in Multiple Sclerosis treatment. The response of the disease to the different available medications at this moment cannot be predicted, and would be desirable. [17]